US equities |
MU $1,048.01 ▼-3.68% NVDA $231.30 ▼-2.60% SNDK $1,619.58 ▼-4.30% AMD $620.67 ▼-3.90% INTC $106.76 ▼-5.62% SPCX $162.34 ▼-3.14% META $718.81 ▼-0.35% PLTR $197.50 ▲+1.74%
FinancialContent

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.25 +0.07 (+0.18%)
Delayed Quote Updated: 2:29 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Releases Q3 2026 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Launch of Offering of Senior Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
From Polpharma Biologics International AG
Via Business Wire
News headline image
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Releases Q2 2026 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >